PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 …
U.S. Food and Drug Administration (FDA) accepts New Drug …
WEB4 hours ago · BERLIN, Germany I October 09, 2024 I Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application …
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of …
WEB12 hours ago · KEYNOTE-689 is the first Phase 3 trial to demonstrate statistically significant and clinically meaningful improvement in EFS in the intent-to-treat population in the …
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for …
WEB11 hours ago · TEL AVIV, Israel I October 08, 2024 I Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the United States (U.S.) Food and Drug
Boehringer Ingelheim and Circle Pharma announce new research ...
WEB4 hours ago · INGELHEIM, Germany and SOUTH SAN FRANCISCO, CA, USA I October 09, 2024 I Boehringer Ingelheim and Circle Pharma (Circle) announce a new research …
TREMFYA® (guselkumab) receives U.S. FDA approval for adults …
WEBSep 12, 2024 · The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA ® showed highly statistically significant rates of endoscopic …
Sarclisa approved in the US as the first anti-CD38 therapy in ...
WEBSep 21, 2024 · Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and …
Viridian Therapeutics Announces Positive Topline Results from ...
WEBSep 10, 2024 · – Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in …
Boehringer Ingelheim announces plans to advance potential new …
WEBSep 5, 2024 · INGELHEIM, Germany and BASEL, Switzerland I September 5, 2024 I Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I …
Datopotamab deruxtecan showed clinically meaningful overall …
WEBMay 28, 2024 · References : 1. National Cancer Institute. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer, 1975-2017. Accessed May 2024. 2. Ahn M-J, …